AMPHASTAR PHARMACEUTICALS IN (AMPH)

US03209R1032 - Common Stock

38.7  -0.47 (-1.2%)

After market: 38.7 0 (0%)

News Image
18 days ago - InvestorPlace

7 Biotech Stocks to Buy on the Dip: June 2024

With health being a top priority over wealth generation, these biotech stocks to buy on the dip enjoy a sound framework for speculation.

News Image
a month ago - NAIC-BetterInvesting

BetterInvesting™ Magazine Update on Amphastar Pharmaceuticals Inc. and Medtronic PLC

/PRNewswire/ -- The Editorial Advisory and Securities Review Committee of BetterInvesting Magazine today announced Amphastar Pharmaceuticals Inc. (NASDAQ:...

News Image
2 months ago - InvestorPlace

Patent Peril: 3 Stocks at Risk From the FTC’s Drug Crusade

The FTC is putting these three drug stocks at risk by trying to strip their therapies of protection from generics.

News Image
2 months ago - InvestorPlace

AMPH Stock Earnings: Amphastar Pharma Beats EPS, Misses Revenue for Q1 2024

AMPH stock results show that Amphastar Pharma beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.

News Image
2 months ago - BusinessInsider

AMPH Stock Earnings: Amphastar Pharma Beats EPS, Misses Revenue for Q1 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Amphastar Pharma (NASDAQ:AMPH) just reported results for the first quarter of 2...

News Image
5 months ago - Seeking Alpha

Amphastar Pharmaceuticals Non-GAAP EPS of $0.88 misses by $0.03, revenue of $178.1M beats by $4.77M (NASDAQ:AMPH)

Amphastar Pharmaceuticals reports Q4 financial results with a Non-GAAP EPS of $0.88, missing estimates by $0.03, while revenue of $178.1M beats expectations...

News Image
5 months ago - Investor's Business Daily

CRISPR Therapeutics Stock Shows Rising Relative Strength, Hits 90+

CRISPR Therapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating.

News Image
5 months ago - Market News Video

AMPH Crosses Below Key Moving Average Level

News Image
5 months ago - InvestorPlace

3 Once-in-a-Lifetime Biotech Stocks With Unprecedented Surge Potential

As the new business cycle gets started, here are some biotech stocks with potential that investors should pay attention to.

News Image
6 months ago - Investor's Business Daily

Axsome Therapeutics Stock Showing Leadership, Earns 91 RS Rating

Axsome Therapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating.

News Image
6 months ago - Investor's Business Daily

Cassava Sciences Stock Continues Showing Rising Relative Strength

Cassava Sciences sees its Relative Strength Rating move into the elite 90-plus level.

News Image
6 months ago - Investor's Business Daily

Eli Lilly, Crispr, Biogen Lead Pharma And Biotech Stocks To Great Expectations In 2024

Between buyouts, obesity drugs and neuroscience progress, biotech stocks stand to gain.

News Image
7 months ago - Investor's Business Daily

Cytokinetics Stock Jumps To Higher RS Level; Shoots Up On Heart Drug Study

On Thursday, Cytokinetics stock cleared a key performance benchmark, with its Relative Strength Rating jumping to 99 from 89 the day before.

News Image
7 months ago - Investor's Business Daily

Recursion Pharm Showing Market Leadership As Biotech Stocks Shoot Higher

On Tuesday, Recursion Pharm stock reached a key technical benchmark, seeing its Relative Strength Rating jump to 91 from 88 the day before.

News Image
7 months ago - InvestorPlace

3 Stocks at the Forefront of Medical Innovation

Boring businesses and industries typically show new faces when technology comes around; today, these biotech stocks are leading the way.